The Ocular Hypertension pipeline market research report provides an overview of the Ocular Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects.
Ocular Hypertension Pipeline Drugs Market by Key Targets
Some of the targets of the Ocular Hypertension pipeline drugs market are Prostaglandin F2 Alpha Receptor, Beta 1 Adrenergic Receptor, Beta 2 Adrenergic Receptor, Rho Kinase, Alpha 2 Adrenergic Receptor, Carbonic Anhydrase 2, Phosphodiesterase 5, Prostaglandin E2 Receptor EP2 Subtype, Soluble Guanylate Cyclase, and 5-Hydroxytryptamine Receptor 1A. Prostaglandin F2 Alpha Receptor has the highest number of pipeline products.
Ocular Hypertension Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Ocular Hypertension Pipeline Drugs Market
Some of the mechanisms of action of the Ocular Hypertension pipeline drugs market are Prostaglandin F2 Alpha Receptor Agonist, Beta 1 Adrenergic Receptor Antagonist, Beta 2 Adrenergic Receptor Antagonist, Rho Kinase Inhibitor, Alpha 2 Adrenergic Receptor Agonist, Carbonic Anhydrase 2 Inhibitor, Phosphodiesterase 5 Inhibitor, Prostaglandin E2 Receptor EP2 Subtype Agonist, Soluble Guanylate Cyclase Activator, and 5-Hydroxytryptamine Receptor 1A Agonist.
Ocular Hypertension Pipeline Drugs Market, by Mechanisms of Action
For more mechanisms of action insights, download a free report sample
Key Routes of Administration in the Ocular Hypertension Pipeline Drugs Market
The routes of administration in the Ocular Hypertension pipeline drugs market are ophthalmic, intraocular, intravitreal, intravenous, oral, parenteral, buccal, conjunctival, intraarticular, and nasal.
Ocular Hypertension Pipeline Drugs Market, by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Ocular Hypertension Pipeline Drugs Market
The molecule types in the Ocular Hypertension pipeline drugs market are small molecule, gene therapy, antisense RNAi oligonucleotide, cell therapy, and protein. Small molecule has the highest number of pipeline products.
Ocular Hypertension Pipeline Drugs Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Ocular Hypertension Pipeline Drugs Market Companies
Some of the key companies in the Ocular Hypertension pipeline drugs market are NicOx SA, Santen Pharmaceutical Co Ltd, Ocular Therapeutix Inc, Betaliq Inc, Kowa Co Ltd, Laboratoires Thea SA, Aadi Bioscience Inc, AbbVie Inc, Aerie Pharmaceuticals Inc, and Angelini Spa.
Ocular Hypertension Pipeline Drugs Market, by Key Companies
To know more about key companies, download a free report sample
Market Report Overview
| Key Targets | Prostaglandin F2 Alpha Receptor, Beta 1 Adrenergic Receptor, Beta 2 Adrenergic Receptor, Rho Kinase, Alpha 2 Adrenergic Receptor, Carbonic Anhydrase 2, Phosphodiesterase 5, Prostaglandin E2 Receptor EP2 Subtype, Soluble Guanylate Cyclase, and 5-Hydroxytryptamine Receptor 1A |
| Key Mechanisms of Action | Prostaglandin F2 Alpha Receptor Agonist, Beta 1 Adrenergic Receptor Antagonist, Beta 2 Adrenergic Receptor Antagonist, Rho Kinase Inhibitor, Alpha 2 Adrenergic Receptor Agonist, Carbonic Anhydrase 2 Inhibitor, Phosphodiesterase 5 Inhibitor, Prostaglandin E2 Receptor EP2 Subtype Agonist, Soluble Guanylate Cyclase Activator, and 5-Hydroxytryptamine Receptor 1A Agonist |
| Key Routes of Administration | Ophthalmic, Intraocular, Intravitreal, Intravenous, Oral, Parenteral, Buccal, Conjunctival, Intraarticular, and Nasal |
| Key Molecule Types | Small Molecule, Gene Therapy, Antisense Rnai Oligonucleotide, Cell Therapy, and Protein |
| Key Companies | NicOx SA, Santen Pharmaceutical Co Ltd, Ocular Therapeutix Inc, Betaliq Inc, Kowa Co Ltd, Laboratoires Thea SA, Aadi Bioscience Inc, AbbVie Inc, Aerie Pharmaceuticals Inc, and Angelini Spa |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).
- Reviews of pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.
- Evaluation of Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to pipeline therapeutics for Ocular Hypertension (Ophthalmology).
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
- Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology)
- Classify potential new clients or partners in the target demographic
- Develop tactical initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics
- Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline
Key Stakeholders
Table of Contents
Tables
List of Tables
Number of Products under Development for Ocular Hypertension, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Ocular Hypertension – Pipeline by Aadi Bioscience Inc, 2022
Ocular Hypertension – Pipeline by AbbVie Inc, 2022
Ocular Hypertension – Pipeline by Aerie Pharmaceuticals Inc, 2022
Ocular Hypertension – Pipeline by Angelini Spa, 2022
Ocular Hypertension – Pipeline by Betaliq Inc, 2022
Ocular Hypertension – Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022
Ocular Hypertension – Pipeline by D. Western Therapeutics Institute Inc, 2022
Ocular Hypertension – Pipeline by Future Medicine Co Ltd, 2022
Ocular Hypertension – Pipeline by Glaukos Corp, 2022
Ocular Hypertension – Pipeline by Graybug Vision Inc, 2022
Ocular Hypertension – Pipeline by Ikarovec Ltd, 2022
Ocular Hypertension – Pipeline by Jenivision Inc, 2022
Ocular Hypertension – Pipeline by Kowa Co Ltd, 2022
Ocular Hypertension – Pipeline by Laboratoires Thea SA, 2022
Ocular Hypertension – Pipeline by Laboratorios Sophia SA de CV, 2022
Ocular Hypertension – Pipeline by Lee’s Pharmaceutical Holdings Ltd, 2022
Ocular Hypertension – Pipeline by MediPrint Ophthalmics Inc, 2022
Ocular Hypertension – Pipeline by Neurim Pharmaceuticals Ltd, 2022
Ocular Hypertension – Pipeline by NicOx SA, 2022
Ocular Hypertension – Pipeline by Noveome Biotherapeutics Inc, 2022
Ocular Hypertension – Pipeline by Ocular Therapeutix Inc, 2022
Ocular Hypertension – Pipeline by pH Pharma Co Ltd, 2022
Ocular Hypertension – Pipeline by Qlaris Bio Inc, 2022
Ocular Hypertension – Pipeline by Santen Pharmaceutical Co Ltd, 2022
Ocular Hypertension – Pipeline by Senju Pharmaceutical Co Ltd, 2022
Ocular Hypertension – Pipeline by Shenzhen Hornetcorn Bio-technology Company Ltd, 2022
Ocular Hypertension – Pipeline by Skye Bioscience Inc, 2022
Ocular Hypertension – Pipeline by Sun Pharma Advanced Research Company Ltd, 2022
Ocular Hypertension – Pipeline by Sun Pharmaceutical Industries Ltd, 2022
Ocular Hypertension – Pipeline by Sustained Nano Systems LLC, 2022
Ocular Hypertension – Pipeline by Sylentis SAU, 2022
Ocular Hypertension – Pipeline by TaeJoon Pharmaceuticals Co Ltd, 2022
Ocular Hypertension – Pipeline by ViSci Ltd, 2022
Ocular Hypertension – Pipeline by Visus Therapeutics Inc, 2022
Ocular Hypertension – Pipeline by Whitecap Biosciences LLC, 2022
Ocular Hypertension – Dormant Projects, 2022
Ocular Hypertension – Dormant Projects, 2022 (Contd..1)
Ocular Hypertension – Discontinued Products, 2022
Graphs
List of Figures
Number of Products under Development for Ocular Hypertension, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022












